Baidu
map

Annals of Surgery:中性粒细胞/淋巴细胞比值预测IPMN相关侵袭癌

2016-09-27 MedSci MedSci原创

目的:评估中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR),和导管内乳头状黏液性肿瘤(IPMN)患者存在侵袭癌之间的关系。背景:NLR和PLR是与侵袭性恶性肿瘤(包括胰腺癌)患者的总生存率相关的炎症标志物。方法:我们对1997年1月到2015年7月,病例证实IPMN、进行手术切除的272例患者,进行了回顾性分析。计算了NLR和PLR,结合人口、临床和影像数据,对IPMN相关侵袭癌

目的:评估中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR),和导管内乳头状黏液性肿瘤(IPMN)患者存在侵袭癌之间的关系。

背景:NLR和PLR是与侵袭性恶性肿瘤(包括胰腺癌)患者的总生存率相关的炎症标志物。

方法:我们对1997年1月到2015年7月,病例证实IPMN、进行手术切除的272例患者,进行了回顾性分析。计算了NLR和PLR,结合人口、临床和影像数据,对IPMN相关侵袭癌的可能性进行评估。

结果:在IPMN相关侵袭癌患者中,NLR和PLR显著升高(P < 0.001)。多变量分析显示,NLR值大于4(P<0.001)、IPMN囊肿尺寸>3cm (P < 0.001)、影像学上可见增强的固体成分(P = 0.014)、主胰管扩张超过5 mm (P < 0.001)和黄疸(P<0.001)是具有统计学意义的变量。开发的预测统计模型其预测指数为0.895。在预测列线图中使用具有统计学意义的变量,可以预测是否存在IPMN相关侵袭癌。

结论:NLR是存在IPMN相关侵袭癌的独立预测指标。需要进一步的前瞻性研究来评估NLR的预测能力,以及如何将研究发现运用到临床上。

原始出处:

Gemenetzis, Georgios MD;et al.Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.Annals of Surgery: September 14, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943721, encodeId=753a1943e217f, content=<a href='/topic/show?id=dcda14415b6' target=_blank style='color:#2F92EE;'>#PMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14415, encryptionId=dcda14415b6, topicName=PMN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Tue Aug 01 11:37:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021538, encodeId=256120215389f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Jul 20 11:37:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877681, encodeId=d5a018e76815e, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Sep 04 04:37:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296612, encodeId=4ff5129661223, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302036, encodeId=5eb4130203639, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426316, encodeId=5ea01426316be, content=<a href='/topic/show?id=d5de9998b3' target=_blank style='color:#2F92EE;'>#IPMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9998, encryptionId=d5de9998b3, topicName=IPMN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38624055926, createdName=TZF0805, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
    2017-08-01 huangdf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1943721, encodeId=753a1943e217f, content=<a href='/topic/show?id=dcda14415b6' target=_blank style='color:#2F92EE;'>#PMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14415, encryptionId=dcda14415b6, topicName=PMN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Tue Aug 01 11:37:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021538, encodeId=256120215389f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Jul 20 11:37:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877681, encodeId=d5a018e76815e, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Sep 04 04:37:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296612, encodeId=4ff5129661223, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302036, encodeId=5eb4130203639, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426316, encodeId=5ea01426316be, content=<a href='/topic/show?id=d5de9998b3' target=_blank style='color:#2F92EE;'>#IPMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9998, encryptionId=d5de9998b3, topicName=IPMN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38624055926, createdName=TZF0805, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1943721, encodeId=753a1943e217f, content=<a href='/topic/show?id=dcda14415b6' target=_blank style='color:#2F92EE;'>#PMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14415, encryptionId=dcda14415b6, topicName=PMN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Tue Aug 01 11:37:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021538, encodeId=256120215389f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Jul 20 11:37:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877681, encodeId=d5a018e76815e, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Sep 04 04:37:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296612, encodeId=4ff5129661223, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302036, encodeId=5eb4130203639, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426316, encodeId=5ea01426316be, content=<a href='/topic/show?id=d5de9998b3' target=_blank style='color:#2F92EE;'>#IPMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9998, encryptionId=d5de9998b3, topicName=IPMN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38624055926, createdName=TZF0805, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
    2017-09-04 chg121
  4. [GetPortalCommentsPageByObjectIdResponse(id=1943721, encodeId=753a1943e217f, content=<a href='/topic/show?id=dcda14415b6' target=_blank style='color:#2F92EE;'>#PMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14415, encryptionId=dcda14415b6, topicName=PMN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Tue Aug 01 11:37:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021538, encodeId=256120215389f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Jul 20 11:37:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877681, encodeId=d5a018e76815e, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Sep 04 04:37:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296612, encodeId=4ff5129661223, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302036, encodeId=5eb4130203639, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426316, encodeId=5ea01426316be, content=<a href='/topic/show?id=d5de9998b3' target=_blank style='color:#2F92EE;'>#IPMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9998, encryptionId=d5de9998b3, topicName=IPMN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38624055926, createdName=TZF0805, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1943721, encodeId=753a1943e217f, content=<a href='/topic/show?id=dcda14415b6' target=_blank style='color:#2F92EE;'>#PMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14415, encryptionId=dcda14415b6, topicName=PMN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Tue Aug 01 11:37:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021538, encodeId=256120215389f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Jul 20 11:37:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877681, encodeId=d5a018e76815e, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Sep 04 04:37:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296612, encodeId=4ff5129661223, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302036, encodeId=5eb4130203639, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426316, encodeId=5ea01426316be, content=<a href='/topic/show?id=d5de9998b3' target=_blank style='color:#2F92EE;'>#IPMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9998, encryptionId=d5de9998b3, topicName=IPMN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38624055926, createdName=TZF0805, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1943721, encodeId=753a1943e217f, content=<a href='/topic/show?id=dcda14415b6' target=_blank style='color:#2F92EE;'>#PMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14415, encryptionId=dcda14415b6, topicName=PMN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Tue Aug 01 11:37:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021538, encodeId=256120215389f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Jul 20 11:37:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877681, encodeId=d5a018e76815e, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Sep 04 04:37:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296612, encodeId=4ff5129661223, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302036, encodeId=5eb4130203639, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426316, encodeId=5ea01426316be, content=<a href='/topic/show?id=d5de9998b3' target=_blank style='color:#2F92EE;'>#IPMN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9998, encryptionId=d5de9998b3, topicName=IPMN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38624055926, createdName=TZF0805, createdTime=Thu Sep 29 10:37:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
    2016-09-29 TZF0805

相关资讯

《中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2016年版)》发布

中性粒细胞缺乏伴发热患者是一组特殊的疾病人群。由于免疫功能低下,炎症的症状和体征常不明显,病原菌及感染灶也不明确,发热可能是感染的唯一征象,如没有给予及时恰当的抗菌药物治疗,感染相关死亡率高。因此,充分认识中性粒细胞缺乏伴发热患者的相关风险、诊断方法以及如何合理使用抗菌药物,对于降低中性粒细胞缺乏伴发热的发生和病死风险至关重要。参考国际指南并结合国内流行病学资料、细菌耐药检测数据以及抗菌药物临床应

Nature:体内微生物促进中性粒细胞衰老加重炎症性疾病

                                  &

Nature:中性粒细胞——乳腺癌肺转移的重要“帮凶”

尽管科学家们已经在癌细胞靶向药物开发方面取得显著进展,但治疗转移性肿瘤的治疗方法通常不是特别有效。许多研究表明癌细胞对它们所处的微环境存在依赖性,因此靶向肿瘤中的非癌细胞组成成分可能是新型治疗方法开发的重要基础。但是人们对于肿瘤生长和转移过程中宿主应答所发挥的作用仍了解较少,限制了新型治疗方法的开发。   在一项发表在国际学术期刊Nature上的最新研究中,来自英国弗朗西斯克里克

Stroke:白淋比升高,急性脑出血患者预后较差

背景:越来越多的证据表明,炎症机制参与了脑内出血引起的脑损伤。研究者评估外周血白细胞计数和中性粒细胞淋巴细胞比率(NLR)对脑出血患者的预后的作用。方法:对急性自发性脑出血患者进行回顾性分析。获得入院时白细胞总数、中性粒细胞绝对计数,和淋巴细胞绝对计数并计算从入院时NLR。研究终点是3个月内死亡或主要残疾的发生。结果:177例受试者纳入研究。94(53.1%)例有不良的结果。绝对中性粒细胞计数、淋

Neurology:脑缺血患者溶栓前中性粒细胞高,患者预后差

目的:为了确定缺血性卒中(IS)患者,静脉给予rtPA溶栓前,较高的中性粒细胞计数与症状性脑出血(sICH)和3月不良预后之间的关系。方法:在里尔和赫尔辛基群体研究中,给予IS患者rtPA治疗前,检测血液中白细胞,中性粒细胞以及淋巴细胞计数。主要终点为sICH(欧洲急性脑卒中Ⅱ定义)。次要终点为死亡以及3个月极好预后(mRS分数0-1或等于卒中前),良好预后(mRS分数为0-2或等于卒中前)。结果

胰腺炎发生的始作俑者

瑞典隆德大学的研究人员可能发现了民众患急性胰腺炎的原因及病情转归。研究结果对急性胰腺炎药物的研发和选择具有重要的借鉴作用。 大家都知道,若中性粒细胞被过度激活,则会引起胰腺出现炎症反应。然而,直到现在,是什么原因导致中性粒细胞出现激活还没有一个令人满意答案。因此,隆德大学的三个研究小组同时开始研究,以寻找到令人满意的答案。 隆德大学的Henrik Thorlacius教授说道:“我们的研究表明,中

Baidu
map
Baidu
map
Baidu
map